Guerbet: 2023 Strategic Priorities
Retrieved on:
Monday, January 16, 2023
Prostate cancer, European Medicines Agency, Algorithm, Face, HSG, Hysterosalpingography, Liver, X-ray, Environment, Watson (computer), Microparticle, Research, Google Images, Lymphogram, IBM Watson Health, Intellectual property, Iodine, Growth, Lipiodol, Intelligence, Liver cancer, MRI, Investment, Acquisition, EMA, Risk management, Medical imaging, Guerbet, Mer (software distribution)
Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
Key Points:
- Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.
- In Europe, the European Medicines Agency (EMA) review is expected in the second half of the year.
- Guerbet also plans to divest the Occlugel technology acquired in 2018, including several ranges of microspheres for use in embolization.
- Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.